Peter A Argenta

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery
    Peter Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA Electronic address
    Gynecol Oncol 133:78-82. 2014
  2. doi Vulvar reconstruction using the "lotus petal" fascio-cutaneous flap
    Peter A Argenta
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, USA Electronic address
    Gynecol Oncol 131:726-9. 2013
  3. doi Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA Electronic address
    Gynecol Oncol 131:368-73. 2013
  4. doi Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study
    P A Argenta
    Department of Obstetrics and Gynecology, The University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    BJOG 120:795-800. 2013
  5. doi Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
  6. pmc Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients
    John D Andersen
    Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 609, 420 Delaware St, SE Minneapolis, MN, USA
    J Ovarian Res 3:21. 2010
  7. doi A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009
  8. ncbi Proximal-type epithelioid sarcoma vs. malignant rhabdoid tumor of the vulva: a case report, review of the literature, and an argument for consolidation
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, MN, USA
    Gynecol Oncol 107:130-5. 2007
  9. ncbi Routine pelvic examination during front-line chemotherapy for ovarian cancer: should it play a role?
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis, USA
    J Reprod Med 53:3-7. 2008
  10. ncbi Widespread lymph node metastases in a young woman with FIGO stage IA1 squamous cervical cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Gynecol Oncol 97:659-61. 2005

Collaborators

Detail Information

Publications43

  1. ncbi Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery
    Peter Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA Electronic address
    Gynecol Oncol 133:78-82. 2014
    ..We attempted to characterize the molecular profile of the endometrium of asymptomatic women with morbid obesity before and following bariatric surgery-induced weight loss...
  2. doi Vulvar reconstruction using the "lotus petal" fascio-cutaneous flap
    Peter A Argenta
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, USA Electronic address
    Gynecol Oncol 131:726-9. 2013
    ..We sought to assess the success rates and morbidity in a large series of consecutively treated patients...
  3. doi Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA Electronic address
    Gynecol Oncol 131:368-73. 2013
    ..We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist...
  4. doi Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study
    P A Argenta
    Department of Obstetrics and Gynecology, The University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    BJOG 120:795-800. 2013
    ..To determine the prevalence of occult uterine pathology in asymptomatic, morbidly obese women before and after bariatric surgery-induced weight loss...
  5. doi Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
    ..We aimed to evaluate the feasibility and tolerability of hyperthermic intraperitoneal carboplatin (HIPEC-carboplatin) following secondary cytoreduction for recurrent, platinum-sensitive ovarian cancer...
  6. pmc Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients
    John D Andersen
    Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 609, 420 Delaware St, SE Minneapolis, MN, USA
    J Ovarian Res 3:21. 2010
    ..We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry...
  7. doi A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009
    ..Grade 1 toxicity included headache (1 patient) and bromidrosis (2 patients). Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common...
  8. ncbi Proximal-type epithelioid sarcoma vs. malignant rhabdoid tumor of the vulva: a case report, review of the literature, and an argument for consolidation
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, MN, USA
    Gynecol Oncol 107:130-5. 2007
    ..Proximal" type epithelioid sarcoma (PES) and malignant rhabdoid tumor (MRT) describe a rare subset of vulvar malignancies which share histologic features and an aggressive clinical course...
  9. ncbi Routine pelvic examination during front-line chemotherapy for ovarian cancer: should it play a role?
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis, USA
    J Reprod Med 53:3-7. 2008
    ..To determine if pelvic examination affected management in patients undergoing first-line chemotherapy for ovarian cancer and to determine a threshold of change in tumor size reliably detectable by pelvic examination...
  10. ncbi Widespread lymph node metastases in a young woman with FIGO stage IA1 squamous cervical cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Gynecol Oncol 97:659-61. 2005
    ..This option is particularly appealing for younger or nulliparous patients, in whom fertility may be highly desired...
  11. doi A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 121:112-7. 2011
    ..To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer...
  12. pmc S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival
    Melissa S DeRycke
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
    Am J Clin Pathol 132:846-56. 2009
    ..In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer...
  13. ncbi Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, MMC 395 420 Delaware St SE, Minneapolis, MN, 55455, USA
    Cancer Immunol Immunother 59:1877-84. 2010
    ..Secondary objectives included assessment of safety and immune system activation...
  14. ncbi A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy
    Patricia L Judson
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 95:226-30. 2004
    ....
  15. doi Estrone sulfatase activity in patients with advanced ovarian cancer
    Justin C Chura
    Department of Obstetrics, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 112:205-9. 2009
    ..We sought to identify whether the sulfatase pathway was present in ovarian cancer specimens and then to determine whether a clinical correlation existed between sulfatase activity and survival...
  16. doi The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer
    Rajul Kothari
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:491-5. 2010
    ....
  17. doi Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial
    Levi S Downs
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 120:265-9. 2011
    ....
  18. ncbi On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus
    Kathryn E Dusenbery
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Clin Oncol 28:295-300. 2005
    ....
  19. ncbi A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
    Levi S Downs
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer 112:331-9. 2008
    ..Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide...
  20. ncbi A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 118:19-23. 2010
    ..We sought to evaluate the outcomes and feasibility associated with delivering sequential chemotherapy and radiation in advanced stage endometrial cancer...
  21. ncbi Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: a retrospective analysis and literature review
    Justin C Chura
    Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Division of Gynecologic Oncology, 420 Delaware Street SE, MMC 395, Minneapolis, MN 55455, USA
    Gynecol Oncol 107:79-85. 2007
    ..Consequently, the optimal management strategy is not defined. We reviewed our institution's experience with brain metastasis from endometrial cancer along with the extant medical literature to develop management recommendations...
  22. pmc Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker
    Melissa S DeRycke
    Dept of Laboratory Medicine and Pathology, MMC 609, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    Am J Clin Pathol 134:835-45. 2010
    ....
  23. doi Solitary fibrous tumors arising from the female pelvis
    Thanasak Sueblinvong
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology University of Minnesota, Minneapolis, Minnesota, USA
    Obstet Gynecol 118:470-4. 2011
    ..Solitary fibrous tumor arising from the female genital tract is extremely rare and the management of this condition is controversial...
  24. ncbi Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience
    Joseph J Ivy
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 114:420-3. 2009
    ..We sought to evaluate the complication rate of two separate intraperitoneal chemotherapy port delivery systems used within a single practice...
  25. doi Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies
    Melissa A Geller
    Division of Gynecologic Oncology, University of Minnesota, Department of Obstetrics, Gynecology and Women s Health, Minneapolis, MN 55455, USA
    Eur J Obstet Gynecol Reprod Biol 143:93-7. 2009
    ..To evaluate the feasibility and morbidity of using saline filled tissue expanders (TE) to displace the small bowel during radiation therapy in patients with gynecologic malignancies...
  26. doi Learning about ovarian cancer at the time of diagnosis: video versus usual care
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:370-5. 2010
    ..We evaluated the effects of an educational video on patients' distress, cancer knowledge, coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis...
  27. pmc A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cytotherapy 13:98-107. 2011
    ..We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer...
  28. ncbi Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer
    Patricia L Judson
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, 420 Delaware Street Southeast, MMC 395, Minneapolis, MN 55455, USA
    Gynecol Oncol 91:389-94. 2003
    ....
  29. ncbi A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer
    Levi S Downs
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Gynecol Oncol 95:347-51. 2004
    ..To determine toxicity and establish a maximum tolerated dose of outpatient therapy with ifosfamide, paclitaxel, and carboplatin in women with advanced and recurrent cervical cancer...
  30. ncbi A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer
    Patricia L Judson
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 93:667-70. 2004
    ..To identify the nature and degree of toxicity of Temozolomide in this group of patients...
  31. ncbi Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic
    Sue V Petzel
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    J Genet Couns 22:662-73. 2013
    ..Ease of referral by the introduction of an electronic cancer genetic referral form represents another new direction that may increase genetic risk assessment for high-risk women with ovarian cancer...
  32. ncbi Hysteroscopy and cytology in endometrial cancer
    William H Bradley
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecology Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Obstet Gynecol 104:1030-3. 2004
    ..To estimate the effect of preoperative diagnostic hysteroscopy on peritoneal cytology in patients with endometrial cancer...
  33. ncbi Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system
    Sue V Petzel
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology Masonic Cancer Center and School of Public Health, University of Minnesota, Minneapolis, MN
    Int J Gynecol Cancer 24:1003-9. 2014
    ..We sought to evaluate an electronic referral form to increase referral for genetic risk assessment of women with newly diagnosed epithelial ovarian cancer...
  34. ncbi Steroid-converting enzymes in human ovarian carcinomas
    Justin C Chura
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, Minneapolis, MN, USA
    Mol Cell Endocrinol 301:51-8. 2009
    ..Evaluation of 17beta-HSD and sulfatase activity levels, activity ratios and inhibition patterns may help predict tumor response to endocrine therapy...
  35. pmc Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells
    Caroline H Diep
    Department of Medicine, Hematology, Oncology, and Transplantation Division, University of Minnesota, Minneapolis, MN, USA
    Cell Cycle 12:1433-49. 2013
    ....
  36. ncbi A multi-institutional review of outcomes of endometrial stromal sarcoma
    Charles A Leath
    Department of Obstetrics, Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
    Gynecol Oncol 105:630-4. 2007
    ..To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively...
  37. doi Vulvar cancer in young women: demographic features and outcome evaluation
    Grainger S Lanneau
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 200:645.e1-5. 2009
    ..The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women...
  38. ncbi The effect of anesthesia choice on post-operative outcomes in women undergoing exploratory laparotomy for a suspected gynecologic malignancy
    Colleen Rivard
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, USA Electronic address
    Gynecol Oncol 133:278-82. 2014
    ..To determine how anesthesia choice in women undergoing laparotomy for gynecologic malignancy affects pain control and narcotic use...
  39. ncbi Stage II squamous cell carcinoma of the vagina in a patient with Bloom syndrome: a case report
    Christine S Goudge
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, 420 Delaware Street SE, MMC 395, Minneapolis, MN 55455, USA
    J Reprod Med 52:557-9. 2007
    ..Bloom syndrome (BS) is a rare autosomal recessive disorder characterized by dwarfism and a predisposition to cancer. Squamous cell vaginal cancer is also quite rare and has not before been reported in association with BS...
  40. ncbi Differential gene expression identifies subgroups of ovarian carcinoma
    Amy P N Skubitz
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minn 55455, USA
    Transl Res 148:223-48. 2006
    ..In addition, the genes identified as over-expressed in each set of serous ovarian carcinoma compared with normal tissues may represent potential biomarkers and/or targets for therapy...
  41. doi Results of introducing a rapid recovery program for total abdominal hysterectomy
    Elizabeth Dickson
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis, Minn, USA
    Gynecol Obstet Invest 73:21-5. 2012
    ..To review the impact of implementing a rapid recovery protocol (RRP) for patients undergoing abdominal hysterectomy...
  42. ncbi Vacuum-assisted closure in the treatment of complex gynecologic wound failures
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mount Sinai Medical Center, New York, New York 10029, USA
    Obstet Gynecol 99:497-501. 2002
    ..They are costly and time consuming to treat, and may evolve into chronic, debilitating conditions. Vacuum-assisted closure is a novel wound healing technique applying subatmospheric pressure to wounds to expedite healing...
  43. ncbi Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations
    Douglas A Levine
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4222-7. 2003
    ....